WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet ...

Remibrutinib Shows Early CSU Symptom Relief. REMIBRUTINIB improved itch and hive severity within 12 hours in chronic spontaneous urticaria in Phase III analysis. A pooled analysis ...

March 28 (Reuters) - Incyte said on Saturday its experimental skin disease drug showed long-term reduction of symptoms in two late-stage trials. The company tested the drug, povorcitinib, in patients ...

Consider a house with the water main half shut. The faucets sputter. The toilet runs all night. The garden wilts. You could call a plumber for the faucet, a landscaper for the garden, a different ...

Cognitive symptoms, such as impairments in memory, attention, and executive functioning, are prevalent across a wide range of psychiatric disorders, ...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced the publication of long-term results from a ...

For those with treatment-resistant depression, traditional methods often fall short. Learn about TMS, a non-invasive option.

Patients with treatment-resistant depression who engaged in a single day of treatment with inhaled mebufotenin reported ...

Upadacitinib can resolve Crohn disease symptoms within the first week, regardless of prior biologic therapy exposure. Patients with Crohn disease (CD) treated with upadacitinib 45 mg once daily can ...